These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28001219)

  • 1. High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala.
    Brum-Soares L; Cubides JC; Burgos I; Monroy C; Castillo L; González S; Viñas PA; Urrutia PP
    Rev Soc Bras Med Trop; 2016; 49(6):721-727. PubMed ID: 28001219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
    Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras.
    Escribà JM; Ponce E; Romero Ade D; Viñas PA; Marchiol A; Bassets G; Palma PP; Lima MA; Zúniga C; Ponce C
    Mem Inst Oswaldo Cruz; 2009 Nov; 104(7):986-91. PubMed ID: 20027465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
    de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM
    Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
    Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal follow up of serological response in children treated for Chagas disease.
    Moscatelli G; Moroni S; García Bournissen F; González N; Ballering G; Schijman A; Corral R; Bisio M; Freilij H; Altcheh J
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007668. PubMed ID: 31465522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody drop in newborns congenitally infected by Trypanosoma cruzi treated with benznidazole.
    Chippaux JP; Clavijo AN; Santalla JA; Postigo JR; Schneider D; Brutus L
    Trop Med Int Health; 2010 Jan; 15(1):87-93. PubMed ID: 19968839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a recombinant Trypanosoma cruzi protein antigen to monitor cure of Chagas disease.
    Guevara AG; Taibi A; Alava J; Guderian RH; Ouaissi A
    Trans R Soc Trop Med Hyg; 1995; 89(4):447-8. PubMed ID: 7570896
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease.
    Ghobadifar MA; Kalani N; Gitiforouz M; Mosallanejad Z
    Rev Soc Bras Med Trop; 2014; 47(5):669. PubMed ID: 25467275
    [No Abstract]   [Full Text] [Related]  

  • 11. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission.
    Sosa-Estani S; Cura E; Velazquez E; Yampotis C; Segura EL
    Rev Soc Bras Med Trop; 2009; 42(5):484-7. PubMed ID: 19967227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment.
    Lana Md; Lopes LA; Martins HR; Bahia MT; Machado-de-Assis GF; Wendling AP; Martins-Filho OA; Montoya RA; Dias JC; Albajar-Viñas P; Coura JR
    Mem Inst Oswaldo Cruz; 2009 Dec; 104(8):1139-47. PubMed ID: 20140375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the ELISA-F29 test as an early marker of therapeutic efficacy in adults with chronic Chagas disease.
    Fabbro D; Velazquez E; Bizai ML; Denner S; Olivera V; Arias E; Pravia C; Ruiz AM
    Rev Inst Med Trop Sao Paulo; 2013; 55(3):. PubMed ID: 23740013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina.
    Niborski LL; Grippo V; Lafón SO; Levitus G; García-Bournissen F; Ramirez JC; Burgos JM; Bisio M; Juiz NA; Ayala V; Coppede M; Herrera V; López C; Contreras A; Gómez KA; Elean JC; Mujica HD; Schijman AG; Levin MJ; Longhi SA
    Mem Inst Oswaldo Cruz; 2016 May; 111(6):365-71. PubMed ID: 27223650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study.
    Andrade MC; Oliveira Mde F; Nagao-Dias AT; Coêlho IC; Cândido Dda S; Freitas EC; Coelho HL; Bezerra FS
    Rev Soc Bras Med Trop; 2013; 46(6):776-8. PubMed ID: 24474023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.
    Rumi MM; Pérez Brandán C; Gil JF; D'Amato AM; Ragone PG; Lauthier JJ; Tomasini N; Cimino RO; Orellana V; Lacunza CD; Nasser JR; Basombrío MA; Diosque P
    Acta Trop; 2013 Oct; 128(1):130-6. PubMed ID: 23880286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of anti-B13 antibodies over time in a cohort of chronic infected by Trypanosoma cruzi. Its relationship with specific treatment and clinical status.
    Olivera V; Bizai ML; Arias E; Suasnabar S; Bottasso O; Marcipar I; Fabbro D
    Acta Trop; 2021 Jun; 218():105908. PubMed ID: 33789152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
    Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
    Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summaries for patients. Long-term outcomes of treating nonacute Chagas disease with benznidazole.
    Ann Intern Med; 2006 May; 144(10):I32. PubMed ID: 16702585
    [No Abstract]   [Full Text] [Related]  

  • 20. Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection.
    Fernández MC; González Cappa SM; Solana ME
    Exp Parasitol; 2010 Feb; 124(2):172-80. PubMed ID: 19747482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.